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A B S T R A C T
A decade ago, the drug-target residence time model has been (re-)introduced, which describes the importance of
binding kinetics of ligands on their protein targets. Since then, it has been applied successfully for multiple
protein targets, including GPCRs, for the development of lead compounds with slow dissociation kinetics (i.e.
long target residence time) to increase in vivo eﬃcacy or with short residence time to prevent on-target asso-
ciated side eﬀects. To date, this model has not been applied in the design and pharmacological evaluation of
novel selective ligands for the cannabinoid CB2 receptor (CB2R), a GPCR with therapeutic potential in the
treatment of tissue injury and inﬂammatory diseases. Here, we have investigated the relationships between
physicochemical properties, binding kinetics and functional activity in two diﬀerent signal transduction path-
ways, G protein activation and β-arrestin recruitment. We synthesized 24 analogues of 3-cyclopropyl-1-(4-(6-
((1,1-dioxidothiomorpholino)methyl)-5-ﬂuoropyridin-2-yl)benzyl)imidazoleidine-2,4-dione (LEI101), our pre-
viously reported in vivo active and CB2R-selective agonist, with varying basicity and lipophilicity. We identiﬁed a
positive correlation between target residence time and functional potency due to an increase in lipophilicity on
the alkyl substituents, which was not the case for the amine substituents. Basicity of the agonists did not show a
relationship with aﬃnity, residence time or functional activity. Our ﬁndings provide important insights about
the eﬀects of physicochemical properties of the speciﬁc substituents of this scaﬀold on the binding kinetics of
agonists and their CB2R pharmacology. This work therefore shows how CB2R agonists can be designed to have
optimal kinetic proﬁles, which could aid the lead optimization process in drug discovery for the study or
treatment of inﬂammatory diseases.
1. Introduction
Traditionally, in drug discovery, the aﬃnity or potency of a drug
candidate for a given target was considered a key determinant for in
vivo activity, but later it was found that these parameters do not cor-
relate as well as originally thought [1,2]. In contrast, the binding ki-
netics of a ligand for a given target, in particular slow dissociation ki-
netics and therefore a long target residence time, may be a better
predictor of in vivo eﬃcacy in speciﬁc cases [3–6], as emphasized by
several excellent reviews [7–9]. For example, a correlation was found
between long residence time of Fab-l enoyl reductase inhibitors and
their in vivo activity in a mouse model of tularemia infection, leading to
prolonged survival of the mice [3,4]. Recently, this “drug-target re-
sidence time model” has aided several clinical-stage drug development
programs [10,11] by selecting compounds with high eﬃcacy [12], or
reduced on-target toxicities [13]. However, the association rate is in-
creasingly recognized as well as an important factor in determining a
ligand’s functional activity. For example, slowly associating ligands
may decrease on-target related side eﬀects by preventing high target
occupancy and fast target activation [14], while fast associating ligands
may have an inﬂuence in prolonged activity if rebinding occurs [15].
Retrospective analysis of marketed drugs for G protein-coupled re-
ceptors (GPCRs), an important class of drug targets, revealed that the
beneﬁcial eﬀects of some of these drugs may be attributed to their long
drug-target residence times [8]. Interestingly, in case of GPCR agonists,
a positive correlation was also found between long residence time and
in vitro eﬃcacy for the Adenosine A2A receptor [16] and the Muscarinic
M3 receptor [17]. For the latter, it was also shown that long target
residence time of an antagonist, i.e. tiotropium, resulted in so-called
kinetic selectivity over the other muscarinic receptor subtypes, thereby
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reducing oﬀ-target side eﬀects [18].
The cannabinoid CB1 and CB2 receptor (CB1R and CB2R) are class A
GPCRs and both part of the endocannabinoid system. This signaling
system comprises the receptors as well as their endogenous ligands,
anandamide (AEA) and 2-arachidoylglycerol (2-AG), which are called
endocannabinoids [19]. The CB1R is mainly found within the central
nervous system [20], which is therefore mainly responsible for the
psycho-active eﬀects of Δ9-tetrahydrocannabinol (THC), the main ac-
tive substituent in cannabis [21]. In contrast, the CB2R is pre-
dominantly abundant in immune cells, is involved in cell migration and
immunosuppression [22,23], and is upregulated during pathophysio-
logical conditions [24]. CB2R activity has been associated with ther-
apeutic beneﬁts in inﬂammatory or immune system related pathologies
[24,25]. Selective activation of the CB2R is therefore associated with
therapeutic beneﬁts and may prevent CB1R-mediated adverse side ef-
fects.
Recently, our group reported on 3-cyclopropyl-1-(4-(6-((1,1-dioxi-
dothiomorpholino)methyl)-5-ﬂuoropyridin-2-yl)benzyl)imidazolei-
dine-2,4-dione (LEI101) (Fig. 1), a promising CB2R partial agonist [26].
LEI101 showed in vivo eﬃcacy in preclinical models of neuropathic
pain and cis-platin-induced nephrotoxicity [26,27]. The CB2R kinetic
proﬁle of LEI101 is unknown, therefore we were interested to system-
atically investigate the binding kinetics and functional activity of this
chemical series.
To this end, we synthesized a library of 24 compounds based on the
scaﬀold of LEI101 (Fig. 1), in which we systematically varied their
basicity and lipophilicity (pKa and LogP) of the R1 (amine) and R2
(alkyl) substituents and determined their equilibrium binding aﬃnity
and Kinetic Rate Index (KRI), a high-throughput measure as an in-
dication for ligand-receptor kinetics [28]. In addition, the full kinetic
proﬁle, as well as functional potency and eﬃcacy in G protein activa-
tion and β-arrestin recruitment, was measured for 14 of these com-
pounds. Correlation analysis of the data identiﬁed a relationship be-
tween target residence time and potency in both signal transduction
pathways due to increased lipophilicity speciﬁcally on the R2 position.
This work provides important insights in the impact of divergent
binding kinetics of LEI101-based agonists on CB2R pharmacology and
the role of physicochemical properties therein. In turn, these insights
show how CB2R agonists can be designed to have optimal kinetic pro-
ﬁles, which will aid the lead optimization process in drug discovery for
the study or treatment of inﬂammatory diseases.
2. Materials and methods
2.1. Chemical and reagents
All common reagents were purchased from commercial sources and
used as received. The agonist library was synthesized as described
previously in van der Stelt et al., 2011 [27], with only small mod-
iﬁcations (see Fig. 2). After puriﬁcation, all compounds had more than
95% purity as determined by Liquid Chromatography Mass
Spectroscopy (LCMS), by measuring UV absorbance at 254 nm and were
fully characterized using 1H NMR and 13C NMR. High resolution mass
spectra were recorded on a mass spectrometer (Thermo Finnigan LTQ
Orbitrap) equipped with an electrospray ion source (ESI) in positive
mode. The spectrometer was calibrated prior to each measurement with
a calibration mixture (Thermo Finnigan). Molecules are drawn with
ChemDraw Professional 16.0. Full details regarding synthetic proce-
dures and compound characterization can be provided upon request
from the corresponding author. Cell culture medium components
(Ham’s F12 Nutrient Mixture, glutamine and antibiotics penicillin,
streptomycin, hygromycin and geneticin), bovine serum albumin (BSA),
polyethylenedimide (PEI), guanosine diphosphate (GDP), dithiothreitol
(DTT) and cannabinoid receptor ligands CP55940 and AM630 were
purchased from Sigma Aldrich (St. Louis, MO). [3H]CP55940 (speciﬁc
activity 141.2 Ci/mmol), [35S]GTPγS (speciﬁc activity 1250 Ci/mmol)
and GF-B/GF-C ﬁlters were purchased from Perkin Elmer (Waltham,
MA). Bicinchoninic acid (BCA) and BCA protein assay reagent were
obtained from Pierce Chemical Company (Rochford, IL). The Path-
Hunter® CHO-K1 CNR1 (CHOK1hCB1_bgal) and CNR2
(CHOK1hCB2_bgal) β-Arrestin Cell Lines and the PathHunter® detection
kit were obtained from DiscoveRx (Fremont, United States). Cell culture
plates were purchased from Sarstedt and 384-well white walled assay
plates from Perkin Elmer. All buﬀers and solutions were prepared using
Millipore water (deionized using a MilliQ A10 Biocel™, with a 0.22 µm
ﬁlter) and analytical grade reagents and solvents. Buﬀers are prepared
at room temperature and stored at 4 °C, unless stated otherwise.
2.2. Cell culture
CHOK1hCB2_bgal cells were cultured in Ham’s F12 Nutrient
Mixture, supplemented with 10% fetal calf serum, 1mM glutamine, 50
U/mL penicillin, 50 μg/mL streptomycin, 300mg/mL hygromycin and
800 μg/mL geneticin in a humidiﬁed atmosphere at 37 °C and 5% CO2,
as reported previously [29]. Cells were subcultured twice a week at a
ratio of 1:20 on 10-cm diameter plates by trypsinization. For membrane
preparation the cells were subcultured 1:10 and transferred to 15-cm
diameter plates. Cells were passaged no longer than 25 times or
3months.
2.3. Membrane preparation
Per batch of membranes, cells on thirty 15-cm ø plates were de-
tached from the bottom by scraping them into 5mL phosphate-buﬀered
saline (PBS), collected in 12mL Falcon tubes and centrifuged for 5min
at 200g (3000 rpm). The pellets were resuspended in ice-cold 50mM
Tris-HCl buﬀer and 5mM MgCl2 (pH 7.4). An Ultra Thurrax homo-
genizer (Heidolph Instruments, Schwabach, Germany) was used to
homogenize the cell suspension. The membranes and cytosolic fractions
were separated by centrifugation at 100,000g (31,000 rpm) in a
Beckman Optima LE-80 K ultracentrifuge (Beckman Coulter Inc.,
Fullerton, CA) at 4 °C for 20min. The pellet was resuspended in 10mL
Fig. 1. Chemical structures of LEI101 (A) and the LEI101-based library of agonists 1–24 (B) synthesized in this study.
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of Tris-HCl buﬀer and 5mM MgCl2 (pH 7.4) and the homogenization
and centrifugation steps were repeated. Finally, the membrane pellet
was resuspended in 10mL 50mM Tris-HCl buﬀer and 5mM MgCl2 (pH
7.4) and aliquots of 250 μL were stored at −80 °C. Membrane protein
concentrations were measured using the BCA method [30].
2.4. [3H]CP55940 equilibrium displacement assay
[3H]CP55940 displacement assays were used for the determination
of aﬃnity (IC50) values of unlabeled ligands. Membrane aliquots con-
taining 1.5 μg of membrane protein were incubated in a total volume of
100 μL assay buﬀer (50mM Tris-HCl buﬀer (pH 7.4), 5 mM MgCl2 and
0.1% BSA) at 25 °C for 2 h in presence of ∼1.5 nM [3H]CP55940. Ten
diﬀerent concentrations of competing ligand were used for determina-
tion of IC50 values, and nonspeciﬁc binding was determined in the
presence of 10 μM AM630. Incubations were terminated and samples
harvested as described by the 96-wells harvest procedure (see below).
2.5. 96-wells harvest procedure
Samples were harvested on 96-wells GF/C ﬁlters, precoated with
25 μL 0.25% (v/v) PEI per well, with rapid vacuum ﬁltration, to sepa-
rate the bound and free radioligand, using a Perkin Elmer 96-wells
harvester (Perkin Elmer, Groningen, The Netherlands). Filters were
subsequently washed ten times with ice-cold assay buﬀer on the 96-well
plate and 5 times on a wash plate. Filter plates were dried at 55 °C for
∼45min, then 25 μL Microscint was added per well (Perkin Elmer,
Groningen, The Netherlands). After 3 h, the ﬁlter-bound radioactivity
was determined by scintillation spectrometry using a Microbeta2® 2450
microplate counter (Perkin Elmer, Boston, MA).
2.6. [3H]CP55940 association assay
To determine association kinetics of [3H]CP55940, it was incubated
at a concentration of∼ 1.5 nM with 1.5 μg of membrane protein in a
total volume of 100 μL of assay buﬀer at 25 °C or 10 °C for a range of
timepoints (90, 60, 30, 25, 20, 15, 10, 5, 3 and 1min). For the assay at
10 °C, an additional time point at 120min was added. Nonspeciﬁc
binding was determined in the presence of 10 μM AM630. Incubations
were terminated and samples harvested as described by the 96-wells
harvest procedure (see above).
2.7. [3H]CP55940 dissociation assay
To determine dissociation kinetics of [3H]CP55940, it was in-
cubated at a concentration of∼ 1.5 nM with 1.5 μg of membrane pro-
tein in a total volume of 100 μL of assay buﬀer at 25 °C or 10 °C for 2 h.
Dissociation was then initiated at a range of timepoints (25 °C: 90, 30,
20, 15, 10, 8, 5, 3, 1 min; 10 °C: 360, 300, 240, 180, 120, 90, 60, 30, 10
and 5min) by addition of 5 μL of AM630 (ﬁnal assay concentration:
10 μM). Nonspeciﬁc binding was determined by addition of 10 μM
AM630 from the start of the assay. Incubations were terminated and
samples harvested as described by the 96-wells harvest procedure (see
above).
2.8. [3H]CP55940 Dual-point competition association assay
For fast determination of the relative kinetics of the agonist library,
the KRI was determined using a dual-point competition association
assay based on previously published methods [28]. The agonists were
incubated at their IC50 concentration (as determined at 25 °C) with
1.5 nM of [3H]CP55940 and 1.5 μg membrane protein in assay buﬀer in
Fig. 2. General procedures. Intermediates 28a–g were obtained from a modiﬁed synthetic approach as compared to van der Stelt et al. [27]: Starting material
pyridinaldehyde 25 was reduced to primary alcohol 26, which was mesylated to intermediate 27. Intermediates 28a–g were obtained by substitution with the
corresponding secondary amine (R1-H). Agonists 1, 9 and 18 were obtained in 4 steps from intermediates 28a–c, by Suzuki coupling, reductive amination and
cyclization using an isocyanate intermediate. For the synthesis of compounds 2–8, 10–17 and 19–24, R2-substituted intermediates 36a–g were obtained in two steps
from 4-bromobenzaldehyde 32, starting with a reductive amination towards intermediates 33a and 33b. In case of R2= cyclopropyl, the R2 substituents was
introduced with a peptide coupling using cyclopropylamine, followed by cyclization to intermediate 36g. 33a was ﬁrst cyclized to the hydantoin and then func-
tionalized with the R2 substituent with an alkylation reaction, resulting in R2-substituted intermediates 36a–f, which were converted in two steps to ﬁnal compounds
using subsequently a Miyaura borylation and Suzuki coupling reaction with intermediates 28a–g [27]. Reagents and conditions: a) NaBH4, DCM:MeOH (2:1), rt,
80 min, 99%; b) Et3N, Ms-Cl, THF, 0 °C, 45min, 72%; c) R1-H, K2CO3, ACN, 50 °C, 49–95%; d) (4-formyl)boronic acid, Pd(PPh3)4, K2CO3, Toluene:EtOH (4:1,
degassed), 50 °C, overnight, 60%-quantitative; e) Methylglycinate, NaBH(OAc)3, THF:MeOH (3:1, dry), rt, overnight; f) NaOCN, AcOH, DCM:water (1:1), rt, 0,5–1; g)
NaOMe, MeOH, rt, overnight, 9–43% (over three steps); h) NaOH, 2-aminoacetamide.HCl, NaBH4, MeOH:water (5:1), rt, 26 h, 79%; i) CDI, DMAP, ACN, 60 °C, 48 h,
48%; j) R2-halide, K2CO3, DMF, 50 °C, 77%-quantitative; k) Glycine, NaOH, NaBH4, MeOH:water (5.5:1), rt, 40 h, 90%; l) I) Et3N, Boc2O, water, rt, overnight, II) DMF
(cat.), SOCl2, DCM, rt, 210min, III) Cyclopropylamine, DCM, 0 °C, overnight, 97%; m) CDI, DMAP, ACN, 60 °C, overnight, 94%; n) KOAc, bis(pinacolato)diboron, Pd
(dppf)Cl2, DMF, 75 °C, overnight; o) Pd(PPh3)4, K2CO3, Toluene:EtOH (4:1, degassed), 75 °C, overnight, 9–87%.
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Table 1
Overview of chemical structures, physicochemical properties, equilibrium aﬃnity and Kinetic Rate Index (KRI) of the LEI101-based agonist library.
Physicochemical properties Binding aﬃnity Kinetic Rate Index
Nr. R1 R2 MW (Da) cLogP pKa pKi ± SEMa KRI ± SEMb
1 H 432 0.4 5.1 5.55 ± 0.08 0.62 ± 0.06
2 447 0.4 5.1 6.61 ± 0.18 0.53 ± 0.06
3 491 0.8 5.1 6.25 ± 0.04 0.67 ± 0.03
4
LEI101
473 0.9 5.1 6.51 ± 0.09 0.52 ± 0.09
5 461 0.9 5.1 7.06 ± 0.12 0.51 ± 0.05
6 475 1.5 5.1 7.66 ± 0.08 0.71 ± 0.05
7 489 1.9 5.1 7.74 ± 0.08 1.06 ± 0.11
8 475 4.4 6.1 7.48 ± 0.10 0.79 ± 0.05
9 H 384 1.3 6.3 5.65 ± 0.05 0.72 ± 0.08
10 398 1.4 6.3 6.06 ± 0.24 0.71 ± 0.06
(continued on next page)
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Table 1 (continued)
Physicochemical properties Binding aﬃnity Kinetic Rate Index
Nr. R1 R2 MW (Da) cLogP pKa pKi ± SEMa KRI ± SEMb
11 442 1.7 6.3 5.35 ± 0.04 0.77 ± 0.05
12 424 1.9 6.3 6.17 ± 0.03 0.67 ± 0.12
13 412 1.9 6.3 6.84 ± 0.25 0.71 ± 0.08
14 426 2.4 6.3 7.13 ± 0.15 0.57 ± 0.08
15 441 2.8 6.3 7.07 ± 0.10 0.67 ± 0.05
16 440 3.0 6.3 6.21 ± 0.20 0.62 ± 0.12
17 475 3.5 6.9 7.67 ± 0.14 0.85 ± 0.13
18 H 382 2.6 8.3 5.48 ± 0.06 0.68 ± 0.07
19 396 2.6 8.3 6.70 ± 0.05 0.60 ± 0.08
20 440 3.0 8.3 6.56 ± 0.13 0.78 ± 0.05
21 425 3.7 8.3 7.92 ± 0.06 0.66 ± 0.14
(continued on next page)
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a total volume of 100 μL, for either 1 or 2 h at 10 °C (t1 and t2, re-
spectively). Nonspeciﬁc binding was determined by addition of 10 μM
AM630 from the start of the assay. Incubations were terminated and
samples harvested as described by the 96-wells harvest procedure (see
above).
2.9. [3H]CP55940 full competition association assay
To determine the kon and koﬀ values of unlabeled competing ligands.
Ligands were incubated at their IC50 concentration (see 2.12 Data
Analysis) in presence of ∼1.5 nM [3H]CP55940 and with 1.5 μg of
membrane protein in a total volume of 100 μL of assay buﬀer at 10 °C
for a range of timepoints (120, 90, 60, 30, 25, 20, 15, 10, 5, 3 and
1min). Nonspeciﬁc binding was determined in the presence of 10 μM
AM630. Incubations were terminated and samples harvested as de-
scribed by the 96-wells harvest procedure (see above).
2.10. [35S]GTPγS assay
G protein activation as a measure for receptor activity was de-
termined by the binding of radiolabeled non-hydrolyzable GTP
([S35]GTPγS) to the receptor [29,31]. To homogenized
CHOK1CB2R_bgal membranes (5 µg) in 20 µL assay buﬀer (50mM Tris-
HCl buﬀer (pH 7.4), 5 mM MgCl2, 150mM NaCl, 1 mM EDTA, 0.05%
BSA and 1mM DTT, freshly prepared every day), 5 µg saponin and 1 µM
GDP were added (ﬁnal assay concentration). To determine the pEC50
and Emax values of the agonist library, the membranes were directly
incubated for 30min at room temperature with various concentrations
of the ligands of interest. The basal level of [S35]GTPγS binding was
measured in untreated membrane samples, and the maximal level of
[S35]GTPγS binding was measured by treatment of the membranes with
10 µM CP55940. Subsequently, [S35S]GTPγS (0.3 nM) was added and
the samples were incubated for 90min at 25 °C on a shaking platform in
a total sample volume of 100 µL. Incubations were terminated and
samples harvested as described by the 96-wells harvest procedure (see
above). Here, samples were harvested on 96-wells GF/B ﬁlters and
washed using buﬀer containing 50mM Tris HCl, pH 7.4 and 5mM
MgCl2.
2.11. PathHunter® β-Arrestin recruitment assay
The assay was performed using the PathHunter® CHOK1CB2R_bgal
cells and β-arrestin recruitment assay kit (DiscoveRx Corporation,
Fremont, CA), as published before [29,32]. Brieﬂy, PathHunter®
CHOK1hCB2R_bgal cells were seeded at a density of 5000 cells per well
of solid white walled 384-well plates (Perkin Elmer, MA, USA) in 20 μL
HAM’s F12 Nutrient Mixture culture medium and incubated overnight
in a humidiﬁed atmosphere at 37 °C and 5% CO2. The cells were sti-
mulated with 5 μL of 50 μM (10 μM ﬁnal assay concentration) of each
agonist (single point assay) or 10 increasing concentrations of each
agonist and incubated for 90min in a humidiﬁed atmosphere at 37 °C
and 5% CO2. The DMSO concentration was the same in each well. The
activity of β-galactosidase was determined using the PathHunter® De-
tection Kit (DiscoveRx Corporation, Fremont, CA), following the sup-
plier’s protocol. In short, the cells were loaded with 12 μL detection
reagent (DiscoveRx Corporation, Fremont, CA) and incubated for 1 h in
the dark at room temperature. Luminescence (400–700 nm), indicated
as relative light units (RLU), was measured on an EnVision multilabel
plate reader (Perkin Elmer, MA, USA), using a Luminescence 700
emission ﬁlter.
2.12. Data analysis
cLogP and pKa values were calculated using ChemDraw®
Professional 16.0 (Perkin Elmer). All experimental data were analyzed
using the nonlinear regression curve ﬁtting program GraphPad Prism 7
(GraphPad Software, Inc., San Diego, CA). From displacement assays at
25 °C, the non-linear regression analysis for one site – Fit Ki was used to
obtain logKi values, which are provided by Prism by direct application
of the Cheng-Prusoﬀ equation [33]: Ki= IC50/(1+ ([L]/KD)) in which
[L] is the exact concentration of [3H]CP55940 determined per experi-
ment (i.e.∼1.5 nM). The kinetic KD (1.24 ± 0.10 nM) of [3H]CP55940
was calculated using the formula KD=koﬀ/kon. The kon
(1.6 ± 0.1×106M−1 s−1) and koﬀ (2.0 ± 0.1×10−3 s−1) of
Table 1 (continued)
Physicochemical properties Binding aﬃnity Kinetic Rate Index
Nr. R1 R2 MW (Da) cLogP pKa pKi ± SEMa KRI ± SEMb
22 439 4.1 8.3 7.56 ± 0.02 1.21 ± 0.07
23 453 4.6 8.3 7.61 ± 0.22 1.03 ± 0.08
24 454 3.3 8.8 5.45 ± 0.09 0.67 ± 0.01
a pKi ± SEM was obtained from a [3H]CP55940 equilibrium displacement assay at 25 °C, on membrane fractions of CHOK1CB2R cells, and determined in three
independent experiments performed in duplicate (N=3 in duplicate).
b KRI ± SEM was obtained from a [3H]CP55940 dual point competition association assay at 10 °C, on membrane fractions of CHOK1CB2R cells (N= 3 in
duplicate).
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[3H]CP55940 at this temperature were determined using an association
and dissociation assay, respectively (three experiments performed in
duplicate, data not shown). The logKi values were converted manually
to pKi values (Table 1). For the kinetic experiments, a concentration
equal to the IC50 value of each agonist was used, as determined from the
non-linear regression analysis for “one site – Fit logIC50”. For non-linear
regression analysis “one site – Fit Ki” and “one site – Fit logIC50” the top
and bottom of the curve were constrained at 100 and 0, respectively.
From association assays, the association rate constant (kon) of
[3H]CP55940 was calculated using the formula kon= (kobs− koﬀ)/[L],
in which [L] is the exact concentration of [3H]CP55940 determined per
experiment. The observed association rate (kobs) was determined with
Prism’s “one-phase exponential association” analysis that uses the fol-
lowing formula: Y=Y0+ (Plateau− Y0) * (1− exp(−kobs * t), where
Y0 is the speciﬁc radioligand binding at time 0 (constrained at 0),
Plateau represents the maximum speciﬁc [3H]CP55940 binding at
equilibrium, kobs is the observed association rate in min−1 and t is the
time in minutes. From dissociation assays, the dissociation rate constant
(koﬀ) of [3H]CP55940 was determined using Prism’s “one-phase ex-
ponential decay” analysis using the following formula:
Y= (Y0−NSB) * exp(−koﬀ * t)+NSB, where koﬀ is the dissociation
rate constant in min−1 and where Y0 is the speciﬁc radioligand binding
at time 0 (constrained at 100). From competition association assays, the
kon and the koﬀ of cold ligands were obtained by non-linear regression
analysis “kinetics of competitive binding” that uses the following
equation [34]:
[RL]=Q * ((k4DIFF)/(KFKS))+ ((k4− KF)/KF) * exp
(−KFt)− ((k4− KS)/KS) * exp(−KSt), using the following variables:
= +−K k [L](10 ) kA 1 9 2
= +−K k [I](10 ) kB 3 9 4
= √ − + ∗ −S ((K K ) 4 k k [L][I](10 ))A B 2 1 3 18
= + +∗K 0.5 (K K S)F A B
= + −∗K 0.5 (K KB S)S A
= −DIFF K KF S
= −Q (B k [L](10 ))/DIFFmax 1 9
Where [RL] is the amount of receptor-ligand complex, [L] is the con-
centration [3H]CP55940 in nM per experiment (∼1.5 nM), [I] depicts
the used concentration of unlabeled competitor in nM, KA and KB are
the observed association rates (kobs) of [3H]CP55940 and the unlabeled
competitor, respectively, k1 and k3 the association rate constants (kon in
M−1 min−1) of [3H]CP55940 (determined per experiment) and the
unlabeled competitor, respectively, k2 and k4 the dissociation rate
constants (koﬀ in min−1) of [3H]CP55940 (0.0115min−1, determined
using three independent dissociation experiments) and the unlabeled
competitor, respectively and t is the time in minutes. The kon
(M−1 min−1) and koﬀ (min−1) provided by Prism were converted
manually to kon (M−1s−1) and koﬀ (s−1). Receptor residence time (RT,
in min) was calculated by taking the reciprocal of the dissociation rate
as follows room temperature= 1/(60 * koﬀ), as koﬀ is in s−1. β-Arrestin
recruitment and GTPγS data were analyzed by Prism’s nonlinear re-
gression analysis “log (agonist) vs. response – variable slope” to obtain
potency (EC50) and eﬃcacy (Emax) values of ligands. The eﬃcacy of all
agonists was normalized to the eﬀects of 10 μM CP55940. The bottom
of the curves were constrained at 0. All data was obtained from three
separate experiments performed in duplicate, unless stated otherwise.
The correlation between two independent variables or data sets was
calculated using a two-tailed Pearson correlation analysis [35]. A P-
value of less than 0.05 was considered signiﬁcant.
3. Results
3.1. Equilibrium binding aﬃnity of the LEI101-library
The aﬃnities of the 24 newly synthesized compounds were de-
termined in a radioligand displacement assay using [3H]CP55940 as the
radiolabeled competitor at a temperature of 25 °C. The structure, aﬃ-
nity (pKi) and physicochemical properties of the library are presented in
Table 1. All compounds showed concentration-dependent displacement
of [3H]CP55940. Compounds 6, 7, 8, 17, 21, 22 and 23, carrying a
propyl or isobutyl group at the R2 position, displayed the highest aﬃ-
nities within the library (pKi> 7.5). In contrast, compounds 3, 11, 16,
and 20, carrying a more bulky methoxyethyl or butyl group at the R2
position, displayed ∼10- to 100-fold lower aﬃnities, ranging from
5.35 ± 0.04 (compound 11) to 6.56 ± 0.13 (compound 20). Com-
pounds 1, 9 and 18, without a substituent at R2, had the lowest aﬃ-
nities (pKi=∼5.5) of the library. On the R1 position, compounds with
a morpholine substituent (compounds 10–17) or a piperazine (com-
pound 24) generally had lower aﬃnities compared to corresponding
dioxidethiomorpholino agonists with the same substituent at the R2
position (e.g. compound 11 vs. 2 and 20, 12 vs. 3 and 21 or 15 vs. 6
and 24).
3.2. High throughput kinetic screening of LEI101-library
Next, the binding kinetics of all compounds were determined using
the high throughput dual-point competition association assay, yielding
Kinetic Rate Index (KRI) values that describe the relative (dissociation)
kinetics of the agonist library compared to the radioligand used,
[3H]CP55940. These experiments, and all the following kinetic ex-
periments, were performed at a reduced temperature of 10 °C to in-
crease the ‘resolution’ of the assay, enabling us to examine the inﬂuence
of diﬀerent physicochemical properties on the relative binding kinetics
of the compounds within the library. Firstly, we validated that the af-
ﬁnities of the molecules were similar (particularly in rank order) at
10 °C as compared to 25 °C using a selection of 8 representative agonists
with low, moderate and high aﬃnity (data not shown). Subsequently,
we used a single concentration of the compounds (1.0× IC50) for de-
termination of the KRI values (Table 1). Most compounds had a KRI
value lower than 1.0, which indicates a residence time (RT) shorter
than that of [3H]CP55940. Compounds 2, 4 and 6 had the lowest KRI
values (0.53 ± 0.06, 0.52 ± 0.09 and 0.51 ± 0.05, respectively),
whereas only 7, 22 and 23 had a KRI value larger than 1.0
(1.06 ± 0.11, 1.21 ± 0.07 and 1.03 ± 0.08, respectively). These
three compounds all have an isobutyl moiety at the R2 position, the
most lipophilic substituent in this series, but have diﬀerent R1 sub-
stituents, a dioxidethiomorpholine (7), a piperidine (22), or a methyl-
piperidine (23).
3.3. Full kinetic proﬁling of the LEI101-library
Based on the results from the KRI screen, twelve agonists were se-
lected for further kinetic characterization. These compounds contained
a dioxidethiomorpholine at the R1 position (group A, compounds 1–7)
or an isobutyl group at the R2 position (group B, compounds 7, 8, 15,
17, 22, 23). Of note, compound 7 belongs to both groups. The mole-
cules comprised a wide range of KRI values between 0.51 and 1.21,
respectively the lowest and highest KRI measured in this agonist li-
brary. Together this allowed a comprehensive investigation of struc-
ture-kinetic relationships at the CB2R. We used a competition associa-
tion assay with [3H]CP55940 that yielded the association- and
dissociation rate constants (kon and koﬀ values, respectively) of the
compounds (Table 2). A signiﬁcant correlation between the KRI values
and koﬀ values was found (Fig. 3A). The association of [3H]CP55940
alone and in presence of a fast dissociating compound (2;
KRI= 0.53 ± 0.06) and a slow dissociating compound (7;
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Table 2
Overview of binding kinetics and functional activity in two signal transduction pathways.
Binding kinetics Functional activity
G protein activationd β-arrestin recruitmente
Nr. Group koﬀ (s−1)a kon (M−1 s−1)a KD (nM)b RT (min)c pEC50 Emax pEC50 Emax
1 A (2.7 ± 1.8)×10−3 (2.2 ± 1.0)×103 1052 ± 264 14 ± 6 6.25 ± 0.09 48 ± 7 6.12 ± 0.23 25 ± 2
2 A (1.2 ± 0.6)×10−2 (1.0 ± 0.7)×105 155 ± 35 2.2 ± 0.8 6.18 ± 0.27 54 ± 13 6.55 ± 0.18 76 ± 15
3 A (7.1 ± 3.3)×10−3 (4.4 ± 2.6)×104 187 ± 25 3.6 ± 1.5 6.06 ± 0.27 60 ± 2 6.58 ± 0.08 45 ± 7
4 (LEI101) A (2.1 ± 0.5)×10−3 (3.0 ± 1.1)×104 76 ± 10 8.8 ± 1.6 6.6 ± 0.2f 65 ± 8f 7.0 ± 0.3f 41 ± 6f
5 A (1.5 ± 0.9)×10−3 (5.3 ± 2.6)×104 26 ± 2 20 ± 8 6.38 ± 0.28 79 ± 14 6.76 ± 0.39 72 ± 10
6 A (5.9 ± 1.3)×10−4 (6.8 ± 1.7)×104 9 ± 2 32 ± 9 7.78 ± 0.07 50 ± 2 7.88 ± 0.10 62 ± 8
7 A/B (2.4 ± 0.1)×10−4 (5.3 ± 0.4)×104 4.5 ± 0.5 71 ± 3 7.94 ± 0.24 60 ± 6 7.83 ± 0.08 56 ± 1
8 B (4.7 ± 0.1)×10−4 (5.9 ± 1.6)×104 9 ± 1 37 ± 5 7.37 ± 0.07 61 ± 6 7.80 ± 0.07 54 ± 6
15 B (4.3 ± 1.8)×10−3 (1.9 ± 0.8)×105 24 ± 2 6.4 ± 2.9 7.18 ± 0.30 65 ± 12 7.21 ± 0.28 64 ± 10
17 B (2.4 ± 0.3)×10−4 (3.7 ± 1.0)×104 8 ± 2 72 ± 8 7.81 ± 0.15 65 ± 7 7.67 ± 0.03 53 ± 2
22 B (2.4 ± 0.1)×10−3 (2.3 ± 0.3)×104 11 ± 1 69 ± 2 6.91 ± 0.32 78 ± 9 8.14 ± 0.08 67 ± 7
23 B (5.9 ± 1.3)×10−4 (7.8 ± 2.1)×104 9 ± 2 31 ± 6 7.61 ± 0.36 77 ± 14 7.89 ± 0.21 59 ± 6
a kon ± SEM and koﬀ ± SEM were obtained from a [3H]CP55940 competition association assay at 10°C, on membrane fractions of CHOK1CB2R cells, and
determined in three independent experiments performed in duplicate (N=3 in duplicate).
b The KD was calculated from koﬀ and kon (N=3 in duplicate) as follows: (KD= koﬀ/kon).
c RT was calculated from koﬀ (N=3 in duplicate) as follows: (RT=1/(60 * koﬀ).
d pEC50 ± SEM and Emax ± SEM were obtained from a [35S]GTPγS assay at 25°C, on membrane fractions of CHOK1CB2R cells (N= 3 in duplicate).
e pEC50 ± SEM and Emax ± SEM were obtained from a PathHunter® β-arrestin recruitment assay at 37°C, on live CHOK1CB2R cells (N= 3 in duplicate).
Fig. 3. Kinetic characterization of LEI101-agonist library. A) Correlation between KRI values and log koﬀ values. Correlation analysis was performed using a two-
tailed Pearson correlation analysis (r= Pearson coeﬃcient). B) Representative competition association curves from [3H]CP55940 alone, or in presence with a long-
(7) or short residence time (2) agonist. C) Kinetic map of log kon vs log koﬀ, where the diagonals represent the ‘Kinetic’ KD value (KD=koﬀ/kon). A–C) Data with error
is the mean and SEM of three independent experiments performed in duplicate and transformed data without error bars (log kon and log koﬀ) are derived from the
mean of three independent experiments performed in duplicate.
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KRI=1.06 ± 0.11) is shown in Fig. 3B. The association of
[3H]CP55940 (koﬀ=1.9 ± 0.1×10−4 s−1, data not shown) in com-
petition with 7 (koﬀ=2.4 ± 0.1× 10−4 s−1), resulted in a small
overshoot after which it reached a plateau at∼ 20%. In contrast, as-
sociation of [3H]CP55940 in competition with 2
(koﬀ=1.2 ± 0.6×10−2 s−1) resulted in a gradual increase of
[3H]CP55940 binding over time. The kon values varied between
2.2 ± 1.0× 103M−1 s−1 (1) and 1.9 ± 0.8× 105M−1 s−1 (15).
Moreover, the variety in kon and koﬀ values was visualized using a ki-
netic map (Fig. 3C), created by plotting the kon values against koﬀ va-
lues. The diagonals represent the ‘kinetic’ KD value (KD= koﬀ/kon) and
show that compounds with similar KD values can have diﬀerent com-
binations of koﬀ and kon values. For example, 2 and LEI101 (4) have a
similar KD value (KD= 10−7 M), but have a more than 0.5 log-diﬀer-
ence both in koﬀ and kon values. Of note, compounds with a KD≤ 10−8
M (black circle) all have dissociation rates slower than 10−3 s−1, while
compounds with a dissociation rate between 10−3 and 10−2 s−1 (da-
shed circle) predominantly had a KD between 10−7 and 10−8 M, due to
a small variety in their kon values. Of note, 1 (R2=H) had a 10-fold
smaller kon value compared to the other compounds, thereby making it
an outlier in the kinetic map (Fig. 3C).
The kinetic KD values of all compounds (Table 2) were compared to
the equilibrium aﬃnities (Ki values) (Fig. 4A). A statistically signiﬁcant
correlation was found between the negative logarithm of the kinetic KD
(10 °C) and the equilibrium pKi (25 °C). Of note, the pKD values were all
0.5 log unit (∼3-fold) higher than the pKi values. A correlation between
pKD and koﬀ or residence time was also identiﬁed (Fig. 4B,C), but not
between pKD and kon values (Fig. 4D).
3.4. Structure-kinetics relationships
The kinetic proﬁle of the compounds was used to derive structure-
kinetics relationships. The longest residence times (RT > 30min) were
displayed by compounds with a propyl (6, RT=32 ± 9min) or iso-
butyl group at the R2 position (7, 8, 17, 22 and 23, RT= 71 ± 3,
37 ± 5, 72 ± 8, 69 ± 2 and 31 ± 6min, respectively). Compounds
2 and 3 displayed the shortest residence times (RT= 2.2 ± 0.8 and
3.6 ± 1.5min, respectively). Interestingly, the residence time of 1 was
similar as LEI101 (4) (RT= 14 ± 6 and 8.8 ± 1.6min for 1 and 4,
respectively), despite a 10-fold lower binding aﬃnity
(pKi= 5.55 ± 0.08 and 6.51 ± 0.09 for 1 and 4, respectively), which
was due to the very low kon value of 1 (2.2 ± 1.0× 103M−1 s−1).
3.5. Inﬂuence of physicochemical properties on aﬃnity and binding kinetics
Next, we analyzed the eﬀects of physicochemical properties on
equilibrium aﬃnity and binding kinetics. Hence, the cLogP (Table 1) of
the compounds with varying alkyl R2 substituents (group A) and the
basicity (pKa) with varying amine R1 substituents (group B) were
plotted against equilibrium aﬃnity, association rate kon and residence
time. The basicity of group B did not correlate with any of the measured
parameters (pKi: Pearson r: 0.02328, p-value= 0.9064; kon: Pearson r:
−0.2213, p-value= 0.6735; RT: Pearson r: 0.3944, p-value=0.5112;
graphs not shown). In case of group A, a near-signiﬁcant correlation
was identiﬁed with their lipophilicity and equilibrium aﬃnity (Pearson
r: 0.692, p-value= 0.0542, Fig. 5A), but not with kon (Pearson r:
0.1452, p-value= 0.7561, Fig. 5B). Interestingly, cLogP of group A was
highly correlated with residence time (Pearson r: 0.8869, p-
value= 0.0078, Fig. 5C). Noteworthy, this correlation was not
Fig. 4. Comparison between equilibrium binding aﬃnity and binding kinetics. A–D) Correlation plots of equilibrium aﬃnity (pKi) with the negative logarithmic
transformation of kinetic aﬃnity (pKD) (A), residence time (RT) (B), dissociation rate koﬀ (C) and association rate kon (D). All data with errors is the mean and SEM of
three independent experiments performed in duplicate. Transformed data without error bars (KD, log kon and log koﬀ) are derived from the mean of three independent
experiments performed in duplicate. Correlation analysis was performed using a two-tailed Pearson correlation analysis (r= Pearson coeﬃcient).
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observed with the R1 substituents of group B (Fig. 6).
3.6. Inﬂuence of binding kinetics on functional activity
Finally, the inﬂuence of residence time on functional activity of the
compound library was investigated. To this end, both groups were
characterized in two functional assays: GTPγS binding and β-arrestin
recruitment (Table 2). All compounds displayed partial agonism in both
assays relative to CP55940. The highest intrinsic eﬃcacy was observed
for 5 in the G protein activation assay (Emax= 79 ± 14%), whereas
agonist 2 had the highest eﬃcacy in the β-arrestin recruitment assay
(Emax= 76 ± 15%). The lowest eﬃcacy was observed for 1 in both
functional assays (β-arrestin: Emax= 25 ± 2%; GTPγS:
Emax= 48 ± 7%). Generally, agonists showed a lower eﬃcacy for β-
arrestin recruitment, except for agonists 2, 6 and 15 (Emax β-arrestin:
76 ± 15, 62 ± 8 and 64 ± 10 compared to Emax GTPγS: 54 ± 13,
50 ± 2 and 65 ± 12, respectively), although these diﬀerences were
not signiﬁcant. Indeed, no correlation was observed between the eﬃ-
cacies of the compounds in the two functional assays (Pearson r:
0.4247, p-value=0.1688, correlation graphs not shown). In addition,
no correlation between residence time and in vitro eﬃcacy was identi-
ﬁed (GTPγS Pearson r: 0.00621, p-value: 0.9895; β-arrestin Pearson r:
Fig. 5. Correlation plots of lipophilicity and binding kinetics of group A agonists. A–C) Correlation plot of equilibrium aﬃnity (A), association rate kon (B) or
residence time (RT) (C) with cLogP values. Correlation analysis was performed using a two-tailed Pearson correlation analysis (r= Pearson coeﬃcient). All data
shown with errors are the mean and SEM of three independent experiments performed in duplicate.
Fig. 6. Correlation plots of lipophilicity and binding kinetics of group B agonists. Correlation plot of residence time (RT) and cLogP values. Correlation analysis was
performed using a two-tailed Pearson correlation analysis (r= Pearson coeﬃcient). Data shown with errors are the mean and SEM of three independent experiments
performed in duplicate.
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0.1053, p-value 0.8222, graphs not shown). For example, the long re-
sidence time of agonists 6, 7, 8, 17, 22 and 23 did not have a higher
eﬃcacy than the other agonists in either functional assay. In fact,
agonist 2 with the shortest residence time (2.2 ± 0.8min) had a very
moderate eﬃcacy in GTPγS (54 ± 13%), and the highest eﬃcacy of all
agonists for β-arrestin recruitment (76 ± 15%).
The potencies ranged from 6.06 ± 0.27 (3) to 7.94 ± 0.24 (7) in
the GTPγS assay, whereas in the β-arrestin recruitment assay the po-
tencies ranged from 6.12 ± 0.23 (1) to 8.14 ± 0.08 (22). In contrast
to eﬃcacy, the potency of the compounds was similar and highly cor-
related in the two functional assays (Pearson r: 0.8445, p-value <
0.0005). In general the compounds showed a higher potency in β-ar-
restin recruitment assays. For example, 22 showed a 17-fold higher
potency for β-arrestin recruitment compared to G protein activation
(pEC50= 8.14 ± 0.08 and 6.91 ± 0.32, respectively).
Notably, nanomolar potency (pEC50 > 7.5) was only displayed by
agonists with a residence time of at least 30min as exempliﬁed by
compounds 6, 8 and 23 (with residence times of 32 ± 9, 37 ± 5 and
31 ± 6min, respectively) and compounds 7, 17 and 22
(RT=71 ± 3, 72 ± 8 and 69 ± 2min, respectively). A statistically
signiﬁcant correlation was found of the residence times of group A with
functional potency for both G protein activation and β-arrestin re-
cruitment (Fig. 7A,B). Interestingly, the residence times of group B did
not correlate with either potency or eﬃcacy (GTPγS Emax Pearson r:
0.0021, p-value: 0.9968; pEC50 Pearson r: 0.3391, p-value: 0.5108; β-
arrestin Emax Pearson r: −0.2591, p-value: 0.6200; pEC50 Pearson r:
0.6586, p-value: 0.1549, graphs not shown).
4. Discussion
4.1. Kinetic characterization of LEI101-based agonists
Recently, drug discovery research has focused on the development
of selective CB2R agonists for the treatment of tissue injury and in-
ﬂammatory diseases that avoid inducing CB1R-mediated psychoactive
side eﬀects. CB2R knockout mice show enhanced pathology in various
inﬂammatory disease models, including heart, liver or kidney injury
and inﬂammatory pain, thereby supporting the notion that CB2R plays
an essential role in these conditions. Despite compelling proof-of-con-
cept data obtained in preclinical pain models, several CB2R agonists
lacked eﬃcacy in phase 2 clinical trials for unknown reasons [29,36].
Drug-target binding kinetics and their inﬂuence on functional ac-
tivity are increasingly considered in drug discovery because it may aid
in the design of lead compounds [2]. Therefore, we have investigated
the relationships between functional activity and binding kinetics of a
series of agonists, based on the CB2R-selective agonist LEI101, which
showed in vivo eﬃcacy in the treatment of neuropathic pain and in-
ﬂammation-induced tissue damage [26,27].
In this study, radioligand binding assays were performed with
[3H]CP55940, an agonistic radioligand commonly used to determine
CBR pharmacology [37], including binding kinetics [38,39]. Recently,
Sykes et al. showed the importance of using physiological concentra-
tions of sodium when determining binding kinetics at the muscarinic
M3 receptor [40]. However, in this study sodium ions were absent in all
assays where the agonist [3H]CP55940 was used to prevent that the
receptor population was forced into a predominantly inactive state, i.e.
for which an agonist would have a low aﬃnity [41]. In addition, in our
system we have never observed a biphasic interaction for agonists,
which would prohibit the use of the Motulsky-Mahan mathematical
model as it describes binding of a ligand to a single site, e.g. receptor
[34,42]. Hence, we also did not apply GTP to force the receptor po-
pulation in a single (inactive) state. Importantly, we believe that it is
unlikely that the omission of sodium salts and/or GTP would result in a
diﬀerent rank order of binding kinetics of the agonist library. This line
of thought is further corroborated by the study on tiotropium and
NVA237 in presence of sodium ions that resulted in shorter residence
times, but the same rank order [40].
The measured equilibrium binding aﬃnities corresponded to pre-
viously determined structure-activity relationships (SAR) for this scaf-
fold [27]. Using a high-throughput kinetic screening assay, based on its
equivalent for the Adenosine A1 receptor [28], agonists with
R1=dioxidethiomorpholine (group A) and R2= isobutyl (group B)
were selected for full kinetic characterization (Fig. 3A). We found that
the kinetic proﬁle of the agonists had smaller variations in kon values,
but larger variations in koﬀ values, which were visualized using a ki-
netic map of the agonist library (Fig. 3C). For this series of compounds,
binding aﬃnity was mostly inﬂuenced by their dissociation rate, as il-
lustrated by a signiﬁcant correlation with koﬀ values, but not with kon
values. (Fig. 4C,D). This observation was similar as reported for the
adenosine A2A receptor [16,17], but in contrast to reports on β2 adre-
nergic receptors and the hERG channel, for which the association rate
was found to be the main driving force in ligand aﬃnity [43,44].
4.2. The role of physicochemical properties on binding kinetics and
functional activity
Previously, it has been shown that controlling physicochemical
properties such as lipophilicity and basicity can lead to ‘tuned drug-
target binding kinetics [8,45,46]. Therefore we divided our library into
two groups in which we systematically varied either the lipophilicity or
the basicity at diﬀerent locations of the scaﬀold. This way, we could
investigate the relationships between physicochemical properties,
binding kinetics and functional activity of these agonists, for which two
independent signaling pathways were used; G protein activation and β-
arrestin recruitment.
A signiﬁcant correlation was found between increasing lipophilicity
Fig. 7. Correlation plots of residence time and potency of Group A agonists. Correlation plot of potency (pEC50) in G protein activation (A) or β-Arrestin (B) with
residence time (RT). Correlation analysis was performed using a two-tailed Pearson correlation analysis (r= Pearson coeﬃcient). Data shown with errors are the
mean and SEM of three independent experiments performed in duplicate.
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at the R2 position of the LEI101 scaﬀold and residence time (group A
agonists, Fig. 5C), but not for the R1 position (group B agonists, Fig. 6).
By dividing our compound library in two parts, we showed that there is
a lipophilic binding domain in the receptor targeted by the R2 sub-
stituents. Occupying this pocket increases binding aﬃnity due to de-
creased dissociation rate. Hence, it is not the overall lipophilicity of a
molecule that determines its dissociation rate, but rather the lipophi-
licity at a speciﬁc position of the scaﬀold [45]. These ﬁndings ﬁt well
with the observation that any relationships between physicochemical
properties and binding kinetics are both ligand and target speciﬁc and
constitute the molecular underpinning of the lipophilic eﬃciency index
[47].
Currently, there is no CB2R crystal structure available to validate the
positioning of this lipophilic binding domain, but a lipophilic binding
domain was identiﬁed in the active site of CB1R, formed by six amino
acid residues [48,49], of which four (i.e. Val1143.32, Tyr1915.39,
Leu1925.40 and Met2756.55) are conserved in the CB2R active site [50].
This indicates that these residues may also play a role in the formation
of a lipophilic binding domain responsible for the increased residence
time of LEI101-based agonists with lipophilic R2 substituents.
All compounds were identiﬁed as partial agonists in two signaling
pathways, G protein activation and β-arrestin recruitment relative to
CP55940 that behaved as a full agonist [51]. From these so-called ‘end-
point’ assays no obvious biased agonism was observed, although these
molecules have diﬀerent binding kinetics. However, follow up studies
with regard to the inﬂuence of assay time and readout should be per-
formed to investigate the role of kinetic context on biased agonism
[52]. On a similar note, these functional assays were performed at
diﬀerent temperatures (i.e. 25 °C and 37 °C), which may inﬂuence the
potency and eﬃcacy values of the compounds tested. Although this will
probably not result in a diﬀerence in rank order, it may inﬂuence the
observed lack of biased signaling [52].
Interestingly, nanomolar potency for G protein activation and β-
arrestin recruitment was associated with compounds having a residence
time longer than 30min, as a signiﬁcant correlation between dissocia-
tion rate and functional potency for both assays was identiﬁed (Fig. 7).
Again, this observation was speciﬁc for group A agonists. No correlation
between residence time and functional eﬃcacy was identiﬁed, as was
reported for the Adenosine A1 receptor [53]. This observation is in
contrast with the previously reported positive correlation found be-
tween residence time and eﬃcacy, but not potency, for the Adenosine
A2A receptor and Muscarinic M3 receptor [16]. Of note, for the Ade-
nosine A2A receptor these molecules showed signiﬁcant longer re-
sidence times than the LEI101-based agonist library.
4.3. Target-speciﬁc binding kinetics in drug discovery
Previously, the CB2R binding kinetics of CP55940, as well as some
other synthetic cannabinoid ligands (e.g. JWH133, HU308) and en-
docannabinoids were reported [42]. Because CP55940 was measured in
both studies, we could use its binding kinetics as reference to compare
the binding kinetics of the ligands tested in the two diﬀerent studies.
Interestingly, the kinetic proﬁle of this agonist library shows remark-
able diﬀerences compared to the reported binding kinetics of some
structurally diﬀerent synthetic ligands for CB2R, like JWH133 and
SR144528 and endocannabinoids anandamide (AEA) and noladin ether
(NE), which all had divergent, but relatively fast kinetics [54]. For these
molecules, the association rate was the main driving force for their
aﬃnity. Knowledge of the kinetic binding parameters of a target’s en-
dogenous ligands is important for two reasons: 1) it is an indication of
the ligand binding kinetics necessary to maintain homeostasis and 2)
these play a major role in deﬁning the pharmacological eﬀect of a drug,
as they have to compete with the endogenous ligands for binding to the
active site [55,56]. Notably, LEI101, identiﬁed to be in vivo active in the
treatment of neuropathic pain and inﬂammation-induced tissue damage
[26,27], has similar binding kinetics as 2-AG, relative to CP55940 (10-
fold slower kon, 10-fold faster koﬀ) [54]. This may indicate that slow
association plays a role in the in vivo eﬃcacy of LEI101. Interestingly,
HU308 and JWH133, also in vivo active CB2R-selective agonists
[29,57,58], had slower association rates [54], but a similar dissociation
rate, relative to CP55940 (20–50-fold slower kon, similar koﬀ). This may
indicate that the optimal kinetic proﬁle of in vivo active CB2R agonists is
ﬂexible, or may be dependent on disease type and/or progression. Al-
though, it is noted that species diﬀerences between mouse and human
CB2R have not been taken into account.
Interestingly, slowly associating ligands may decrease on-target
related side eﬀects by preventing high target occupancy and fast target
activation [14]. This could be important, because prolonged activation
of CB2R is hypothesized to interfere with the ECS homeostasis [54,59].
Speciﬁcally, local, transient activation of CB2R by endocannabinoids
may lead to immunosuppression in the early phases of the immune
response, perhaps via apoptotic mechanisms [60,61]. Rapid restoration
of cellular activity might also be required to counteract potential in-
fectious threats [62]. This indicates that the optimal kinetic proﬁle of
novel molecules needs to be established according to their functional
activity, and should always be a combination of association and dis-
sociation rates, resulting in an optimal level of receptor occupancy in
vivo [63].
4.4. Conclusion
In summary, we have reported the structure kinetics relationship of
LEI101-based agonists of the cannabinoid CB2 receptor. We identiﬁed
the lipophilicity of R2 position as important feature to increase receptor
residence time, which correlated with increased potency, but not with
eﬃcacy, in two signaling pathways: G protein activation and β-arrestin
recruitment. The ﬁndings of this study provide important insights into
how CB2R agonists can be designed with desired kinetic proﬁles for the
future development of novel treatments of inﬂammatory diseases.
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